The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 601–700 of 1,000
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 66
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 68
Bienkowska, K., Hanley, C. J., & Thomas, G. J. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.686337 · Cited by 71
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 71
Zsíros, E., Duttagupta, P. A., Laniti, D. D., Li, H., Frank, R., Garrabrant, T. A., Hagemann, I. S., Levine, B. L., June, C. H., Zhang, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2777 · Cited by 66
Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 69
Harnessing the Microbiome for Pancreatic Cancer Immunotherapy
Vitiello, G. A., Cohen, D. J., & Miller, G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.005 · Cited by 65
Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve
Jurcak, N. R., & Zheng, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.010 · Cited by 67
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 72
Koustoulidou, S., Hoorens, M. W. H., Dalm, S. U., Mahajan, S., Debets, R., Seimbille, Y., & de Jong, M. (2021) · Cancers · doi:10.3390/cancers13051100 · Cited by 67
Ho, W. J., Erbe, R., Danilova, L., Phyo, Z. H., Bigelow, E., Stein-O’Brien, G., Thomas, D. L., Charmsaz, S., Groß, N., Woolman, S., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02363-6 · Cited by 67
Yamauchi, M., Gibbons, D. L., Zong, C. C., Fradette, J. J., Bota‐Rabassedas, N., & Kurie, J. M. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.05.001 · Cited by 67
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 71
Cancer Associated Fibroblasts - An Impediment to Effective Anti-Cancer T Cell Immunity
Koppensteiner, L., Mathieson, L., O’Connor, R. A., & Akram, A. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887380 · Cited by 69
Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers
Zhang, H., Cao, K., Xiang, J., Zhang, M., Zhu, M., & Xi, Q. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216345 · Cited by 68
The Kynurenine Pathway and Indole Pathway in Tryptophan Metabolism Influence Tumor Progression
Lu, Z., Zhang, C., Zhang, J., Su, W., Wang, G., & Wang, Z. (2025) · Cancer Medicine · doi:10.1002/cam4.70703 · Cited by 81
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65
Liu, D., Badeti, S., Dotti, G., Jiang, J.-G., Wang, H., Dermody, J. J., Soteropoulos, P., Streck, D. L., Birge, R. B., & Liu, C. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00617-7 · Cited by 68
The CXCL12 Crossroads in Cancer Stem Cells and Their Niche
López-Gil, J. C., Martín-Hijano, L., Hermann, P. C., & Sáinz, B. (2021) · Cancers · doi:10.3390/cancers13030469 · Cited by 68
WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer
Du, W., Menjivar, R. E., Donahue, K. L., Kadiyala, P., Velez-Delgado, A., Brown, K. L., Watkoske, H. R., He, X., Carpenter, E. S., Angeles, C. V., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220503 · Cited by 64
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 72
Nedaeinia, R., Najafgholian, S., Salehi, R., Goli, M., Ranjbar, M., Nickho, H., Javanmard, S. H., Ferns, G. A., & Manian, M. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02146-5 · Cited by 69
Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance
Beatty, G. L., Eghbali, S. Z., & Kim, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175232 · Cited by 64
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
CAR T Cell Locomotion in Solid Tumor Microenvironment
Nguyen, D., Ogando‐Rivas, E., Liu, R., Wang, T., Rubin, J. A., Jin, L., Tao, H., Sawyer, W. W., Méndez‐Gómez, H. R., Cascio, M., et al. (2022) · Cells · doi:10.3390/cells11121974 · Cited by 65
Szabó, P. M., Vajdi, A., Kumar, N., Tolstorukov, M. Y., Chen, B. J., Edwards, R. H., Ligon, K. L., Chasalow, S. D., Chow, K.-H., Shetty, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28480-9 · Cited by 71
Licaj, M., Mhaidly, R., Kieffer, Y., Croizer, H., Bonneau, C., Meng, A., Djerroudi, L., Mujangi-Ebeka, K., Hocine, H. R., Bourachot, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45595-3 · Cited by 71
Piwócka, O., Piotrowski, I., Suchorska, W. M., & Kulcenty, K. I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1343523 · Cited by 69
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Bojmar, L., Zambirinis, C. P., Hernandez, J. M., Chakraborty, J., Shaashua, L., Kim, J., Johnson, K. E., Hanna, S., Aşkan, G., Burman, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03075-7 · Cited by 69
Self-citationKadel, D., Zhang, Y., Sun, H., Zhao, Y., Dong, Q., & Qin, L. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09461-z · Cited by 62
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
Hilmi, M., Nicolle, R., Bousquet, C., & Neuzillet, C. (2020) · Cancers · doi:10.3390/cancers12102969 · Cited by 66
Domen, A., Quatannens, D., Zanivan, S. R., Deben, C., Audenaerde, J. R. M. V., Smits, E., Wouters, A., Lardon, F., Roeyen, G., Verhoeven, Y., et al. (2021) · Cancers · doi:10.3390/cancers13050987 · Cited by 64
An, H., Hou, D., Yang, J., Wang, Z., Wang, M., Zheng, R., Zhang, N.-Y., Hu, X., Wang, Z., Wang, L., et al. (2023) · Science Advances · doi:10.1126/sciadv.abq8225 · Cited by 63
Giordano, F. A., Layer, J. P., Leonardelli, S., Friker, L. L., Turiello, R., Corvino, D., Zeyen, T., Schaub, C., Müller, W. C., Sperk, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48416-9 · Cited by 63
Mirlekar, B., Michaud, D. E., Searcy, R., Greene, K., & Pylayeva‐Gupta, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0710 · Cited by 66
Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
Colombo, M., Mirandola, L., Chiriva‐Internati, M., Basile, A., Locati, M., Lesma, E. A., Chiaramonte, R., & Platonova, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01823 · Cited by 65
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 62
PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Mucileanu, A., Chira, R. I., & Mircea, P. A. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2116 · Cited by 60
Advances on the roles of tenascin-C in cancer
Yilmaz, A., Loustau, T., Salomé, N., Surendran, S. P., Li, C., Tucker, R. P., Izzi, V., Lamba, R., Koch, M., & Orend, G. (2022) · Journal of Cell Science · doi:10.1242/jcs.260244 · Cited by 62
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 66
Errarte, P., Larrinaga, G., & Lopez, J. I. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.09.004 · Cited by 60
Herting, C. J., Karpovsky, I., & Lesinski, G. B. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09988-w · Cited by 60
Wang, Z., Moresco, P., Yan, R., Li, J., Gao, Y., Biasci, D., Yao, M., Pearson, J., Hechtman, J. F., Janowitz, T., et al. (2022) · Apollo (University of Cambridge) · doi:10.17863/cam.81675 · Cited by 61
Self-citationKondoh, N., & Mizuno‐Kamiya, M. (2022) · Cancers · doi:10.3390/cancers14122884 · Cited by 61
Lee, Y. E., Go, G.-Y., Koh, E.-Y., Yoon, H.-N., Seo, M., Hong, S.-M., Jeong, J. H., Kim, J.-C., Cho, D., Kim, T. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006130 · Cited by 61
Takeyama, Y., Kato, M., Tamada, S., Azuma, Y., Shimizu, Y., Iguchi, T., Yamasaki, T., Gi, M., Wanibuchi, H., & Nakatani, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.013 · Cited by 61
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 61
Gonda, T. A., Fang, J., Salas, M. C., Do, C., Hsu, E., Zhukovskaya, A., Siegel, A., Takahashi, R., Bujanda, Z. A. L., Drake, C. G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0285 · Cited by 60
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
Pham, T. D., Shields, M. A., Spaulding, C., Principe, D. R., Li, B., Underwood, P. W., Trevino, J. G., Bentrem, D. J., & Munshi, H. G. (2021) · Cancers · doi:10.3390/cancers13030440 · Cited by 64
Suppression of T cell responses in the tumor microenvironment
Frey, A. B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.096 · Cited by 60
Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell
Wang, Z., Sun, J., Feng, Y., Tian, X., Wang, B., & Zhou, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5016-z · Cited by 60
Omland, S. H., Wettergren, E. E., Mollerup, S., Asplund, M., Mourier, T., Hansen, A. J., & Gniadecki, R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3663-0 · Cited by 61
Chen, G., Wang, Y., Wu, P., Zhou, Y., Yu, F., Zhu, C., Li, Z., Yu, H., Wang, K., Li, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01482 · Cited by 59
Small molecules as theranostic agents in cancer immunology
Li, J., Valkenburgh, J. S. V., Hong, X., Conti, P. S., Zhang, X., & Chen, K. (2019) · Theranostics · doi:10.7150/thno.37218 · Cited by 61
Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61
Donahue, K. L., Watkoske, H. R., Kadiyala, P., Du, W., Brown, K. L., Scales, M. K., Elhossiny, A. M., Espinoza, C. E., Opsahl, E. L. L., Griffith, B. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0100 · Cited by 60
The tumor microenvironment is an ecosystem sustained by metabolic interactions
Kay, E. J., & Zanivan, S. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115432 · Cited by 63
Kandimalla, R., Tomihara, H., Banwait, J. K., Yamamura, K., Singh, G. P., Baba, H., & Goel, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4044 · Cited by 57
The role of microbiome in pancreatic cancer
Li, J., Zhu, M., Kashyap, P., Chia, N., Tran, N. H., McWilliams, R. R., Bekaii‐Saab, T., & Ma, W. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09982-2 · Cited by 60
Optimizing the manufacturing and antitumour response of CAR T therapy
Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 60
Park, H.-R., Shiva, A., Cummings, P., Kim, S., Kim, S., Lee, E., Leong, A., Chowdhury, S., Shawber, C. J., Carvajal, R. D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2838 · Cited by 59
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Sushil Kumar, K., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 56
Li, Y., Xiang, S., Pan, W., Wang, J., Zhan, H., & Liu, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166860 · Cited by 58
Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta
O’Connor, R. A., Martinez, B. R., Koppensteiner, L., Mathieson, L., & Akram, A. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221532 · Cited by 63
Chuangchot, N., Jamjuntra, P., Yangngam, S., Luangwattananun, P., Thongchot, S., Junking, M., Thuwajit, P., Yenchitsomanus, P., & Thuwajit, C. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01684-7 · Cited by 58
Adaptations of neutrophils in cancer
Ng, M. S. F., Cerezo‐Wallis, D., Ng, L. G., & Hidalgo, A. (2025) · Immunity · doi:10.1016/j.immuni.2024.12.009 · Cited by 60
Caballero‐Baños, M., Benítez‐Ribas, D., Tabera, J., Varea, S., Vilana, R., Bianchi, L., Ayuso, J. R., Pagés, M., Carrera, G., Cuatrecasas, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.008 · Cited by 57
Kilvaer, T. K., Rakaee, M., Hellevik, T., Östman, A., Strell, C., Bremnes, R. M., Busund, L., Dønnem, T., & Martínez-Zubiaurre, I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192157 · Cited by 58
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 59
Dixit, A. K., Sarver, A. G., Zettervall, J., Huang, H., Zheng, K., Brekken, R. A., & Provenzano, P. P. (2022) · JCI Insight · doi:10.1172/jci.insight.153242 · Cited by 61
CAF-immune cell crosstalk and its impact in immunotherapy
Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 61
Owen, J. S., Clayton, A., & Pearson, H. B. (2022) · Biomolecules · doi:10.3390/biom13010067 · Cited by 60
Wei, R., Song, J., Liu, C., Zhao, Z., Liu, X., Yamamoto, M., Tsukamoto, T., Nomura, S., Liu, F., Wang, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217475 · Cited by 56
The fibroinflammatory response in cancer
Xiao, Z., & Puré, E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00798-8 · Cited by 65
Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
Feist, M., Zhu, Z., Dai, E., Ma, C., Liu, Z., Giehl, E., Ravindranathan, R., Kowalsky, S. J., Obermajer, N., Kammula, U. S., et al. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0189-4 · Cited by 56
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies
Benavente, S., Sánchez-García, A., Naches, S., LLeonart, M. E., & Lorente, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.582884 · Cited by 57
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 55
cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer
Kabashima, A., Matsuo, Y., Ito, S., Akiyama, Y., Ishii, T., Shimada, S., Masamune, A., Tanabe, M., & Tanaka, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14297-5 · Cited by 55
Fight the Cancer, Hit the CAF!
Papait, A., Romoli, J., Stefani, F. R., Chiodelli, P., Montresor, M. C., Agoni, L., Silini, A. R., & Parolini, O. (2022) · Cancers · doi:10.3390/cancers14153570 · Cited by 55
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 61
Cumming, J., Maneshi, P., Dongre, M., Alsaed, T., Dehghan-Nayeri, M. J., Ling, A., Pietras, K., Patthey, C., & Öhlund, D. (2025) · Cancer Research · doi:10.1158/0008-5472.can-23-3252 · Cited by 61
Pancreatic cancer microenvironment, to target or not to target?
Carr, R. M., & Fernández-Zapico, M. E. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505948 · Cited by 55
Pinter, M., Weinmann, A., Wörns, M., Hucke, F., Bota, S. I., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617695698 · Cited by 55
Mandili, G., Curcio, C., Bulfamante, S., Follia, L., Ferrero, G., Mazza, E., Principe, M., Cordero, F., Satolli, M. A., Spadi, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001071 · Cited by 54
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 59
Geng, X., Li, L., Luo, Y., Yang, W., Hu, J., Zhao, Z., Cheng, C., Zhang, T., Zhang, Y., Liu, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202203324 · Cited by 54
Lu, J., Wu, L., Sun, Y., Huang, X., Gao, C., Guo, X.-J., Zeng, H., Qu, X.-D., Chen, Y., Wu, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44795-1 · Cited by 55
Car T Cells in Solid Tumors: Overcoming Obstacles
Rojas, J., Diaz, M. P., Palmar, J., Galán‐Freyle, N. J., Morillo, V., Escalona, D., González-Torres, H. J., Torres, W., Quiroz, E. N., Rivera-Porras, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084170 · Cited by 57
Zhu, Y. J., Zhang, L., Zha, H., Yang, F., Hu, C., Chen, L., Guo, B., & Zhu, B. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19398 · Cited by 54
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 55
Lam, B., Shrivastava, S. K., Shrivastava, A., Shankar, S., & Srivastava, R. K. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15413 · Cited by 53
Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells
Arina, A., & Bronte, V. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.006 · Cited by 53
Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises
Mei, L., Du, W., & Ma, W. W. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.03.03 · Cited by 51
Zhang, X., Shen, L., Liu, Q., Hou, L., & Huang, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.039 · Cited by 52
Pratt, H. G., Steinberger, K. J., Mihalik, N. E., Ott, S., Whalley, T., Szomolay, B., Boone, B. A., & Eubank, T. D. (2021) · Cancers · doi:10.3390/cancers14010194 · Cited by 58
Role of Serine Proteases at the Tumor-Stroma Interface
Tagirasa, R., & Yoo, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832418 · Cited by 58
Spatially Resolved Deconvolution of the Fibrotic Niche in Lung Fibrosis
Eyres, M., Bell, J. A., Davies, E. R., Fabre, A., Alzetani, A., Jogai, S., Marshall, B. G., Johnston, D. A., Xu, Z., Fletcher, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111230 · Cited by 54
Akkız, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043941 · Cited by 54
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
